Cytokines, stress, and depressive illness
暂无分享,去创建一个
[1] J. Chambers,et al. Effect of epinephrine-liberated pancreatic substance on uptake of alpha aminoisobutyric acid by isolated perfused rat liver. , 1972, Life sciences. Pt. 2: Biochemistry, general and molecular biology.
[2] H. Anisman,et al. Do early-life events permanently alter behavioral and hormonal responses to stressors? , 1998, International Journal of Developmental Neuroscience.
[3] D. Revicki,et al. Reliability and validity of a health-related quality of life battery for evaluating outpatient antidepressant treatment , 1992, Quality of Life Research.
[4] R. Post,et al. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. , 1992, The American journal of psychiatry.
[5] B. Bush,et al. High-performance liquid chromatography of biogenic amines and metabolites in brain, cerebrospinal fluid, urine and plasma. , 1986, Journal of chromatography.
[6] C. Plata-salamán,et al. Pro-inflammatory and anti-inflammatory cytokine mRNA induction in the periphery and brain following intraperitoneal administration of bacterial lipopolysaccharide , 2001, Brain Research Bulletin.
[7] D. Klein,et al. Predictive value of symptoms of atypical depression for differential drug treatment outcome. , 1992, Journal of clinical psychopharmacology.
[8] W. Banks,et al. Differential transport of rat and human interleukin-1α across the blood–brain barrier and blood–testis barrier in rats , 2000, Brain Research.
[9] J. Rybakowski,et al. Interleukin‐6 Serum Levels in Depressed Patients before and after Treatment with Fluoxetine , 1995, Annals of the New York Academy of Sciences.
[10] N. Rothwell. Cytokines in the Nervous System , 1996, Neuroscience Intelligence Unit.
[11] T. Smith,et al. Major depressive disorder, alcoholism, and reduced natural killer cell cytotoxicity. Role of severity of depressive symptoms and alcohol consumption. , 1990, Archives of general psychiatry.
[12] H. Miyaoka,et al. Depression from interferon therapy in patients with hepatitis C. , 1999, The American journal of psychiatry.
[13] H. Meltzer,et al. Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? , 1993, The American journal of psychiatry.
[14] A K Manatunga,et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. , 2001, The New England journal of medicine.
[15] S. Cohen,et al. Stress and immunity in humans: a meta‐analytic review. , 1993, Psychosomatic medicine.
[16] A. Valentine,et al. Neurological and Psychiatric Adverse Effects of Immunological Therapy , 1995 .
[17] N. Rothwell,et al. Cytokines and the nervous system II: actions and mechanisms of action , 1995, Trends in Neurosciences.
[18] N. Rothwell. Cytokines ‐ killers in the brain? , 1999 .
[19] H. Anisman,et al. Lymphocyte Subsets Associated With Major Depression and Dysthymia: Modification by Antidepressant Treatment , 1995, Psychosomatic medicine.
[20] H. Anisman,et al. Circulating Lymphocyte Subsets in Major Depression and Dysthymia With Typical or Atypical Features , 1998, Psychosomatic medicine.
[21] T. Lundeberg,et al. Activation of Vagal Afferents after Intravenous Injection of Interleukin-1β: Role of Endogenous Prostaglandins , 1998, The Journal of Neuroscience.
[22] C. Plata-salamán,et al. Neither acute nor chronic exposure to a naturalistic (predator) stressor influences the interleukin-1β system, tumor necrosis factor-α, transforming growth factor-β1, and neuropeptide mRNAs in specific brain regions , 2000, Brain Research Bulletin.
[23] R. Roth,et al. The determinants of stress-induced activation of the prefrontal cortical dopamine system. , 1990, Progress in brain research.
[24] R. Dantzer,et al. Lowered Serum Dipeptidyl Peptidase IV Activity is Associated with Depressive Symptoms and Cytokine Production in Cancer Patients Receiving Interleukin-2-Based Immunotherapy , 2001, Neuropsychopharmacology.
[25] B. Prusoff,et al. Scaling of life events. , 1971, Archives of general psychiatry.
[26] H. Anisman,et al. Interleukin-1β production in dysthymia before and after pharmacotherapy , 1999, Biological Psychiatry.
[27] S. Maier,et al. Timecourse and corticosterone sensitivity of the brain, pituitary, and serum interleukin-1β protein response to acute stress , 2000, Brain Research.
[28] W. Banks,et al. Human interleukin (IL) 1 alpha, murine IL-1 alpha and murine IL-1 beta are transported from blood to brain in the mouse by a shared saturable mechanism. , 1991, The Journal of pharmacology and experimental therapeutics.
[29] R. Dantzer,et al. Mechanisms of the behavioural effects of cytokines. , 1999, Advances in experimental medicine and biology.
[30] E. Schmidt,et al. Phenotypic Plasticity of CRF Neurons during Stress a , 1993, Annals of the New York Academy of Sciences.
[31] P. MohanKumar,et al. Interleukin-1 stimulates the release of dopamine and dihydroxyphenylacetic acid from the hypothalamus in vivo. , 1991, Life sciences.
[32] E. Schmidt,et al. Interleukin‐1‐Induced Plasticity of Hypothalamic CRH Neurons and Long‐Term Stress Hyperresponsiveness a , 1998, Annals of the New York Academy of Sciences.
[33] T. Patterson,et al. Reduction of immune function in life stress and depression , 1990, Biological Psychiatry.
[34] M. Demitrack,et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. , 1991, The Journal of clinical endocrinology and metabolism.
[35] P. Müller-Preuss,et al. Effect of bacterial endotoxin and interleukin-1 beta on hippocampal serotonergic neurotransmission, behavioral activity, and free corticosterone levels: an in vivo microdialysis study , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[36] R. Dantzer,et al. Timing and Specificity of the Cognitive Changes Induced by Interleukin-2 and Interferon-&agr; Treatments in Cancer Patients , 2001, Psychosomatic medicine.
[37] C. Weisse,et al. Depression and immunocompetence: a review of the literature. , 1992, Psychological bulletin.
[38] E. Bosmans,et al. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. , 1997, Cytokine.
[39] H. Anisman,et al. Further evidence for the depressive effects of cytokines: Anhedonia and neurochemical changes , 2002, Brain, Behavior, and Immunity.
[40] H. Anisman,et al. Interleukin-2 decreases accumbal dopamine efflux and responding for rewarding lateral hypothalamic stimulation , 1996, Brain Research.
[41] Bruce S. McEwen,et al. INDUCTION OF CORTICOTROPIN-RELEASING HORMONE GENE EXPRESSION BY GLUCOCORTICOIDS: IMPLICATION FOR UNDERSTANDING THE STATES OF FEAR AND ANXIETY AND ALLOSTATIC LOAD , 1998, Psychoneuroendocrinology.
[42] S. Kennedy,et al. Low plasma cortisol in bulimia nervosa patients with reversed neurovegetative symptoms of depression , 1997, Biological Psychiatry.
[43] M. Maes,et al. Major depression and activation of the inflammatory response system. , 1999, Advances in experimental medicine and biology.
[44] H. Anisman,et al. Sensitization to the Effects of Tumor Necrosis Factor-α: Neuroendocrine, Central Monoamine, and Behavioral Variations , 1999, The Journal of Neuroscience.
[45] M. Irwin,et al. Immune correlates of depression. , 1999, Advances in experimental medicine and biology.
[46] E. Bosmans,et al. Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. , 2000, Polish journal of pharmacology.
[47] A. Leon,et al. Measurement of Severity and Treatment Response in Dysthymia , 1993 .
[48] S. Cohen,et al. Depression and immunity: a meta-analytic review. , 1993, Psychological bulletin.
[49] H. Anisman,et al. Lipopolysaccharide, central in vivo biogenic amine variations, and anhedonia , 1998, Neuroreport.
[50] Joseph E LeDoux. Emotion: clues from the brain. , 1995, Annual review of psychology.
[51] C. Nemeroff,et al. The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. , 1996, Molecular psychiatry.
[52] S. Maier,et al. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. , 1998, Psychological review.
[53] E. Bosmans,et al. Depression‐related disturbances in mitogen‐induced lymphocyte responses and interleukin‐1β and soluble interleukin‐2 receptor production , 1991, Acta psychiatrica Scandinavica.
[54] M. Hamilton,et al. Development of a rating scale for primary depressive illness. , 1967, The British journal of social and clinical psychology.
[55] H. Anisman,et al. Effects of interleukin-1β and mild stress on alterations of norepinephrine, dopamine and serotonin neurotransmission: a regional microdialysis study , 1997, Brain Research.
[56] H. Anisman,et al. Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: clinical symptoms and functional impairments. , 1999, The American journal of psychiatry.
[57] A. Caraceni,et al. Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration. , 1993, European journal of cancer.
[58] H. Anisman,et al. Lymphocyte proliferation among major depressive and dysthymic patients with typical or atypical features. , 2000, Journal of Affective Disorders.
[59] M. Ackenheil,et al. Psychoneuroimmunology and the cytokine action in the CNS: Implications for psychiatric disorders , 1998, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[60] H. Anisman,et al. Influence of interleukin-1β on exploratory behaviors, plasma ACTH, corticosterone, and central biogenic amines in mice , 1998, Psychopharmacology.
[61] F. Bloom,et al. Psychopharmacology: The Fourth Generation of Progress , 1995 .
[62] D. Rubinow,et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. , 1987, Annals of internal medicine.
[63] S. Maier,et al. Exposure to Acute Stress Induces Brain Interleukin-1β Protein in the Rat , 1998, The Journal of Neuroscience.
[64] H. Anisman,et al. Multisystem Regulation of Performance Deficits Induced by Stressors , 1991 .
[65] R. Yirmiya. Endotoxin produces a depressive-like episode in rats , 1996, Brain Research.
[66] R. Adams,et al. Coping behavior in depression: report on a new scale. , 1984, Behaviour research and therapy.
[67] R. Dantzer,et al. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] M. Åsberg,et al. A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.
[69] L C Harrison,et al. Diurnal rhythmicity of human cytokine production: a dynamic disequilibrium in T helper cell type 1/T helper cell type 2 balance? , 1997, Journal of immunology.
[70] J. Ceuppens,et al. More exact quantification of interleukin-2 production by addition of anti-Tac monoclonal antibody to cultures of stimulated lymphocytes. , 1987, Journal of immunological methods.
[71] Takashi Yamaguchi,et al. Immobilization stress induces interleukin-1β mRNA in the rat hypothalamus , 1991, Neuroscience Letters.
[72] H. Anisman,et al. Anhedonic and anxiogenic effects of cytokine exposure. , 1999, Advances in experimental medicine and biology.
[73] H. Anisman,et al. Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment , 1999, Neuroscience.
[74] A. Reichenberg,et al. Cytokines, "depression due to a general medical condition," and antidepressant drugs. , 1999, Advances in experimental medicine and biology.
[75] T. Smith,et al. Electroencephalographic sleep and natural killer activity in depressed patients and control subjects. , 1992, Psychosomatic medicine.
[76] A. Dunn,et al. Peripheral administration of interleukin-1 increases extracellular concentrations of norepinephrine in rat hypothalamus: Comparison with plasma corticosterone , 1996, Psychoneuroendocrinology.
[77] H. Anisman,et al. Time-dependent sensitization of corticotropin-releasing hormone, arginine vasopressin and c-fos immunoreactivity within the mouse brain in response to tumor necrosis factor-α , 2001, Neuroscience.
[78] R. Dantzer,et al. Cytokine Actions on Behavior , 1996 .
[79] H. Anisman,et al. Central monoamine and plasma corticosterone changes induced by a bacterial endotoxin: sensitization and cross‐sensitization effects , 2001, The European journal of neuroscience.
[80] A. Turnbull,et al. Cytokine Effects on Neuroendocrine Axes: Influence of Nitric Oxide and Carbon Monoxide , 1996 .
[81] S. Kasper,et al. Abnormal pituitary-adrenal responses to corticotropin-releasing hormone in patients with seasonal affective disorder: clinical and pathophysiological implications. , 1991, The Journal of clinical endocrinology and metabolism.
[82] D. Klein,et al. Antidepressant specificity in atypical depression. , 1988, Archives of general psychiatry.
[83] L. Träskman-bendz,et al. Increased soluble interleukin‐2 receptor concentrations in suicide attempters , 1993, Acta psychiatrica Scandinavica.
[84] T. Harris,et al. Social Origins of Depression: A Study of Psychiatric Disorder in Women , 1979 .
[85] A. Beck,et al. An inventory for measuring depression. , 1961, Archives of general psychiatry.
[86] R. Lazarus,et al. Comparison of two modes of stress measurement: Daily hassles and uplifts versus major life events , 1981, Journal of Behavioral Medicine.
[87] A. Dunn. Endotoxin-induced activation of cerebral catecholamine and serotonin metabolism: comparison with interleukin-1. , 1992, The Journal of pharmacology and experimental therapeutics.
[88] J. Blalock,et al. The syntax of immune-neuroendocrine communication. , 1994, Immunology today.
[89] H. Meltzer,et al. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression , 1993, Psychiatry Research.
[90] C. Plata-salamán,et al. Cytokine interactions and cytokine balance in the brain: relevance to neurology and psychiatry , 1999, Molecular Psychiatry.
[91] P. Sawchenko,et al. A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[92] Bruce Mcewen,et al. Stress, Adaptation, and Disease: Allostasis and Allostatic Load , 1998, Annals of the New York Academy of Sciences.
[93] B. Leonard,et al. Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. , 1994, Journal of affective disorders.
[94] E. Bosmans,et al. Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining , 1992, Psychological Medicine.
[95] G. Asnis,et al. Biological and clinical validation of atypical depression , 1996, Psychiatry Research.
[96] H. Anisman,et al. The Impact of Stressors on Immune and Central Neurotransmitter Activity: Bidirectional Communication , 1993, Reviews in the neurosciences.
[97] V. Arolt,et al. Cytokine Production and Serum Proteins in Depression , 1995, Scandinavian journal of immunology.
[98] M. Wong,et al. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection , 1999, Molecular Psychiatry.
[99] S. Rivest,et al. Stress and Interleukin‐1 β‐Induced Activation of c‐fos, NGFI‐B ann CRF Gene Expression in the Hypothalamic PVN: Comparison Between Sprague‐Dawley, Fisher‐344 and Lewis Rats , 1994, Journal of neuroendocrinology.
[100] Michael Davis,et al. Neurotransmission in the rat amygdala related to fear and anxiety , 1994, Trends in Neurosciences.
[101] R. S. Smith. The macrophage theory of depression. , 1991, Medical hypotheses.
[102] H. Anisman,et al. Behavioral and neurochemical consequences of lipopolysaccharide in mice: anxiogenic-like effects , 1999, Brain Research.
[103] P. MohanKumar,et al. Systemic administration of interleukin-1 stimulates norepinephrine release in the paraventricular nucleus. , 1993, Life sciences.
[104] H. Meltzer,et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. , 1995, Journal of affective disorders.
[105] A. Sluzewska,et al. Indicators of immune activation in depressed patients. , 1999, Advances in experimental medicine and biology.
[106] M. Berk,et al. Acute phase proteins in major depression. , 1997, Journal of psychosomatic research.
[107] Satoshi Obana,et al. Differential Effects of Neuropeptides on Cytokine Production by Mouse Helper T Cell Subsets , 1998, Neuroimmunomodulation.
[108] N. Varney,et al. Psychopharmacology: The Fourth Generation of Progress. , 1996 .
[109] E. Schmidt,et al. Interleukin-1-induced long-lasting changes in hypothalamic corticotropin-releasing hormone (CRH)--neurons and hyperresponsiveness of the hypothalamus-pituitary-adrenal axis , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[110] S. Lightman,et al. Early-life exposure to endotoxin alters hypothalamic-pituitary-adrenal function and predisposition to inflammation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[111] Michael Maes,et al. Evidence for an immune response in major depression: A review and hypothesis , 1995, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[112] M. Wong,et al. Corticotropin Releasing Hormone in the Pathophysiology of Melancholic and Atypical Depression and in the Mechanism of Action of Antidepressant Drugs , 1995, Annals of the New York Academy of Sciences.
[113] H. Anisman,et al. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features , 1999, Molecular Psychiatry.
[114] S. Maier,et al. Cytokine-to-brain communication: a review & analysis of alternative mechanisms. , 1995, Life sciences.